Publicaciones en las que colabora con Javier Angulo Cuesta (16)

2022

  1. Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study

    Journal of Clinical Medicine, Vol. 11, Núm. 4

  2. Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study

    Journal of Clinical Medicine, Vol. 11, Núm. 13

2021

  1. Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Clinical benefit of tamsulosin and the hexanic extract of serenoa repens, in combination or as monotherapy, in patients with moderate/severe luts-bph: A subset analysis of the qualiprost study

    Journal of Clinical Medicine, Vol. 9, Núm. 9, pp. 1-14

2018

  1. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies

    BJU International, Vol. 122, Núm. 6, pp. 1049-1065

2013

  1. Análisis de los factores que influyen en la pérdida hemática en la nefrolitotomía percutánea: registro de la Asociación Española de Urología sobre la posición supina

    Actas Urologicas Espanolas, Vol. 37, Núm. 9, pp. 527-532

  2. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial

    European Urology, Vol. 63, Núm. 2, pp. 283-295

  3. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: A post hoc analysis of a randomized European-Australian Phase 3 trial

    BMC Urology, Vol. 13

  4. Mirabegron for the treatment of overactive bladder: A prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

    International Journal of Clinical Practice, Vol. 67, Núm. 7, pp. 619-632

  5. Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): Positioning statement from the Spanish Association of Urology

    Actas Urologicas Espanolas

2007

  1. Efecto del tabaco sobre la evolución de los tumores de vejiga

    Actas Urologicas Espanolas, Vol. 31, Núm. 4, pp. 349-354

  2. Prevalencia y significado clínico de los cánceres de próstata focales e incidentales

    Actas Urologicas Espanolas, Vol. 31, Núm. 8, pp. 819-824

2006

  1. Significado de la progresión de PSA tras prostatectomía radical. Resultados preliminares

    Actas Urologicas Espanolas, Vol. 30, Núm. 4, pp. 353-358

2005

  1. Efecto de polifenoles de la dieta mediterránea sobre la proliferación y mediadores de la invasividad "in vitro" de la línea de cáncer vesical murino MB-49

    Actas Urologicas Espanolas, Vol. 29, Núm. 8, pp. 743-749

2000

  1. Dolor pelvico cronico: Enfoque multidisciplinario

    Revista de la Sociedad Espanola del Dolor, Vol. 7, Núm. 6, pp. 375-389

1999

  1. Primary bilateral hydatidosis of the psoas muscle

    Journal of Urology, Vol. 161, Núm. 5, pp. 1557-1558